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ABSTRACT 
The findings of trials investigating the effect of L-carnitine administration on glycemic control are controversial. 
This meta-analysis of randomized controlled trials (RCTs) was performed to explore the effects of L-carnitine 
intake on glycemic control. Two authors independently searched electronic databases including MEDLINE, EM-
BASE, Cochrane Library, Web of Science, PubMed and Google scholar from 1990 until February 2019, in order 
to find relevant RCTs. 37 studies with 44 effect sizes met the inclusion criteria and were eligible for the meta-
analysis. L-carnitine supplementation resulted in a significant reduction in fasting plasma glucose (FPG) (WMD: 
-4.57; 95 % CI: -6.88, -2.25), insulin (WMD: -1.21; 95 % CI: -1.85, -0.57), homeostatic model assessment for 
insulin resistance (HOMA-IR) (WMD: -0.67; 95 % CI: -0.90, -0.44) and HbA1C concentrations (WMD: -0.30; 
95 % CI: -0.47, -0.13). L-Carnitine supplementation significantly reduced FPG, insulin, HOMA-IR, and HbA1c 
levels.  
 
Keywords: L-carnitine, glycemic control, insulin resistance, meta-analysis 
 
Abbreviations: FPG: Fasting Plasma Glucose; HOMA-IR: Homeostatic Model Assessment for Insulin Re-
sistance; HbA1c: Hemoglobin A1C 
 
 
INTRODUCTION 
There are many definitions of metabolic 
syndrome (MetS) but most of them include 
three of five cardiovascular disease (CVD) 
risk factors: hypertriglyceridemia, low levels 
of high density lipoprotein-cholesterol (HDL-
C), abdominal obesity, hypertension, and hy-
perglycemia (Murthy et al., 2016). MetS is re-
lated with an increased risk of CVD, non-al-
coholic fatty liver disease (NAFLD), type 2 
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diabetes mellitus (T2DM) and subsequent 
mortality (Ford, 2005; Gami et al., 2007; 
Tabák et al., 2009). As a consequence of lack 
of physical activity and excessive energy in-
take, MetS has become a disease which af-
fects more than 25 % of the world population 
and causes serious concerns worldwide 
(Grundy, 2016). Insulin resistance and dis-
turbed glucose metabolism resulting with hy-
perglycemia are most important in develop-
ment of T2DM and other diseases related to 
MetS (Grundy et al., 2005). 
Carnitine is a dipeptide which is an essen-
tial factor for the membrane transport of acyl-
coenzyme A (CoA) (Suzuki et al., 1982). Car-
nitine deficiency reduces the use of lipids 
which causes serious metabolic defects 
(Takenaka et al., 2007). Many studies have 
found that treatment with carnitine has a sub-
stantial role in glucose tolerance, weight loss, 
fatty acids metabolism and insulin function 
(Molfino et al., 2010; Zhang et al., 2014). A 
relatively recently published meta-analysis by 
Xu et al. (2017), indicated that carnitine sup-
plementation has beneficial effect in patients 
with insulin resistance. Several randomized 
controlled trials (RCTs) have investigated the 
efficacy of carnitine on markers related to 
glycemic control in patients with MetS, but 
their results are inconsistent. Alipour et al. 
(2014) reported that 8 weeks of carnitine sup-
plementation in obese diabetic women on hy-
pocaloric diet significantly reduced fasting 
glucose and insulin resistance. A 8-week car-
nitine supplementation in patients on perito-
neal dialysis improved insulin sensitivity 
(Bonomini et al., 2013). It has also been 
shown that carnitine administration at a dos-
age of 2 g/day for 12 months to subjects with 
T2DM resulted in a significant improvement 
in homeostatic model assessment-insulin re-
sistance (HOMA-IR) (Derosa et al., 2011). 
However, Shirali et al. (2016) indicated that 
L-carnitine plus caffeine in male teen soccer 
players increased their fasting glucose levels. 
Liang et al.(1998) suggested that 3 g/day car-
nitine supplementation during 12 weeks to 
non-insulin dependent diabetes mellitus pa-
tients had no effects on fasting glucose, 
HbA1c, and insulin levels. 
Discrepancies between the studies might 
be due to different concepts of studies as well 
as different formulations and dosages of car-
nitine used. The aim of this paper is to review 
systematically the trials investigating the ef-
fect of L-carnitine supplementation on glyce-
mic control and to perform a meta-analysis in 
order to determine the effects of L-carnitine 
on markers related to glycemic control. 
 
METHODS 
Search strategy 
Two authors independently searched elec-
tronic databases including MEDLINE, EM-
BASE, Cochrane Library, Web of Science, 
PubMed and Google scholar databases from 
1990 until February 2019 for relevant RCTs 
investigating the association between L-car-
nitine intake and glycemic control. The search 
strategy was limited to RCTs conducted in 
English databases and performed in humans. 
The following MeSH and keywords were 
used to identify primary RCTs: intervention 
("L-carnitine" OR "propionyl L-Carnitine" 
OR "Acetyl-L-carnitine" OR "carnitine oro-
tate complex" OR "L-carnitine -L-tartrate" 
AND "supplementation" OR "intake"), and 
parameters ["fasting plasma glucose (FPG)" 
OR "insulin" OR "homeostasis model assess-
ment of insulin resistance (HOMA-IR)" OR 
"HbA1C"]. The reference lists of related 
RCTs and previous reviews were hand-re-
viewed to detect further studies which were 
not captured in primary search. 
 
Inclusion and exclusion criteria 
RCTs fulfilling the following criteria 
were included in meta-analysis: trials on hu-
mans with cross-over design and/or either 
parallel, data analyzing the effect of L-car-
nitine on glycemic parameters extracted from 
RCTs with standard deviation (SD) and 95 % 
confidence interval (CI) for both treatment 
and control groups. Other studies such as in 
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vitro studies, animal experiments, observa-
tional studies, studies with duration below 
two weeks, case reports and studies without a 
control group were excluded from this meta-
analysis. 
 
Data extraction and quality assessment 
Two authors independently (HF and AM) 
screened the articles based on the inclusion 
criteria. As the first step the title and abstract 
of studies were reviewed. Any disagreement 
was resolved by the judgment of the third au-
thor (ZA).  
The following data were extracted from 
selected studies: year of publication, the first 
authors’ name, study location and design, 
dosage of intervention, sample size, duration 
of study, age of subjects, type of disease, the 
mean and SD for glycemic control in each 
treatment group. The quality of the selected 
RCTs was assessed by same authors inde-
pendently using the Cochrane Collaboration 
risk of bias tool based on the following crite-
ria: "allocation concealment, randomization 
generation, outcome assessors and blinding of 
participants, selective outcome reporting, in-
complete outcome data, and other sources of 
bias".  
 
Data synthesis and statistical analysis 
Effects of L-carnitine on the changes of 
glycemic parameters. Weighted mean differ-
ence (WMD) with 95 % CI was used for pool-
ing data to determine effect sizes. The ran-
dom-effect model was used to report the 
pooled effect sizes using 95 % CI. 
 
Heterogeneity and publication bias 
Heterogeneity of included studies was 
evaluated using Cochrane’s Q test and I-
square test. The funnel plot, as well as the 
Beggs’s and Egger’s regression tests was used 
to determine the publication bias. STATA 
11.0 (Stata Corp., College Station, TX) was 
applied for data analysis. 
 
RESULTS 
Characteristics of included studies 
Diagram for study selection is shown in 
Figure 1. 37 studies with 44 effect sizes were 
included in this systematic review and meta-
analysis (Table 1). The studies were pub-
lished between 1998 and 2018. A total of 
2467 subjects, including 1243 persons in in-
tervention and 1224 persons in control 
groups, were recruited in these studies. Stud-
ies were done in China, Iran, Italy, India, 
USA, Japan, Mexico, UK, Lebanon, Korea, 
Spain, Egypt and Iraq. Studies used L-carni-
tine, propionyl L-carnitine, glycine propionyl 
L-carnitine, and acetyl L-carnitine for treat-
ment. The dosages varied between 200 to 
3,000 mg/day, with a duration range between 
23 days and 12 months. 
 
 
Figure 1: Literature search and review flowchart 
for selection of studies 
 
 
EXCLI Journal 2019;18:631-643 – ISSN 1611-2156 
Received: May 16, 2019, accepted: August 03, 2019, published: August 19, 2019 
 
 
634 
Table 1: Characteristics of included primary clinical trials 
Authors (Ref) Publication year Country 
Sample size 
(control/ 
intervention) 
Duration Age (y) (intervention/control) 
Intervention 
(type and dosage) 
Liang et al. 1998 China 23/23 12 weeks 59.4±1.17, 57.9±2.6 3000 mg L-carnitine 
Derosa et al. 2003 Italy 48/46 24 weeks 52±6, 50±7 2000 mg L-carnitine 
Rahbar et al. 2005 Iran 16/19 12 weeks 50.5±4.8, 52.2±2.6 3000 mg L-carnitine 
Santo et al. 2006 Italy 37/37 12 months 61.75±3.03,  61.26±1.6 2000 mg propionyl L-carnitine 
McMackin et al. 2007 USA 36/36 8 weeks ≥ 55 500 mg acetyl-L-carnitine + 200 mg α-lipoic acid 
Malaguarnera et al.  2007 Italy 34/32 24 weeks 101±1.3, 101±1.4 2000 mg L-carnitine 
Morano et al. 2007 Italy 8/8 12 weeks 45-70 2000 mg propionyl L-carnitine 
Morano et al. 2007 Italy 8/8 12 weeks 45-70 2000 mg propionyl L-carnitine + sildenafil 
Yonei et al. 2007 Japan 17/18 8 weeks 40-69 200 mg L-carnitine + 700 conjugated linoleic acid 
Gonzalez-Ortiz et al. 2008 Mexico 6/6 4 weeks 30-60 3000 mg L-carnitine 
Yonei et al. 2008 Japan 17/18 8 weeks 48.3±6.9  600 mg L-carnitine + 500 mg Garcinia cambogia extract  
Malaguarnera et al.  2009 Italy 40/41 12 weeks 49±13, 48±11 2000 mg L-Carnitine 
Galvano et al. 2009 Italy 37/38 16 weeks 30-70 2000 mg L-carnitine + 20 mg simvastatin 
Malaguarnera et al. 2009 Italy 40/40 12 weeks 40-70 2000 mg L-carnitine + 20 mg simvastatine 
Bloomer et al. 2009 USA 15/14 8 weeks 31±11.22, 35±11.61 3000 mg acetyl L-carnitine arginate 
Bloomer et al. 2009 USA 10/4 8 weeks 18-44 1000 mg Glycine propionyl-L-carnitine 
Bloomer et al. 2009 USA 11/5 8 weeks 18-44 3000 mg Glycine propionyl-L-carnitine 
Derosa et al. 2010 Italy 113/114 12 months 51±4, 53±6 2000 mg L-carnitine + 360 mg orlistat 
Malaguarnera et al.  2010 Italy 38/36 24 weeks 47.9±5.4, 47.8±5.8 2000 mg L-carnitine + diet 
Derosa et al. 2010 Italy 110/113 12 months ≥18 2000 mg L-carnitine + 10 mg sibutramine 
Wall et al. 2011 UK 7/7 24 weeks 27.1±5.8, 24.6±5.28 2720 mg L-carnitine + 160 g carbohydrate 
Rafraf et al. 2012 Iran 11/11 8 weeks 34.4±5.48, 36.5±7.33 2000 mg L-carnitine 
Rafraf et al. 2012 Iran 11/11 8 weeks 34.8±6.25, 36.1±7.2 2000 mg L-carnitine + exercise 
Hlais et al. 2012 Lebanon 19/15 12 weeks 55.6±1.70, 51.7±12.31 1000 mg L-carnitine 
Rondanelli et al. 2013 Italy 45/41 2 months 25-45 300 mg L-carnitine + Botanical extracts 
Bonomini et al. 2013 Italy 12/15 120 days ≥18 Glucose-based peritoneal dialysis solution enriched with  L-carnitine (2000 mg/bag) 
Hong et al. 2014 Korea 24/24 12 weeks 30-75 900 mg carnitine orotate complex + 750 mg metformin 
Soare et al. 2014 USA 26/28 6 months 38-55 500 mg acetyl‐L‐carnitine + other substances 
Alipour et al. 2014 Iran 30/30 8 weeks 20-50 2000 mg  L-carnitine + low calorie diet 
Bañuls et al. 2015 Spain 13/15 12 weeks 51.7±7.7 2325 mg L-carnitine enriched bread + soluble fiber 
Bañuls et al. 2015 Spain 15/11 12 weeks 53.8±10.7 2325 mg L-carnitine enriched bread + soluble fiber 
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Table 1 (cont.): Characteristics of included primary clinical trials 
Authors (Ref) Publication year Country 
Sample size 
(control/ 
intervention) 
Duration Age (y) (intervention/control) 
Intervention 
(type and dosage) 
Bae et al. 2015 Korea 39/39 12 weeks 20-70 900 mg carnitine-orotate 
Mosah et al. 2015 Iraq 18/18 12 weeks 33.11±6.53, 32.72±7.0 1000 mg L-carnitine 
Samimi et al. 2016 Iran 30/30 12 weeks 18-40 250 mg carnitine 
Shirali et al. 2016 Iran 10/10 8 weeks 16-18 2000 mg L-carnitine + 6 mg/kg caffeine 
Alavinejad et al. 2016 Iran 26/28 12 weeks 60±5, 59±9 2250 mg L-carnitine 
An et al. 2016 Korea 25/28 12 weeks 49.0±8.2, 50.9±9.1 1980 mg L-carnitine 
Akbarzadeh et al. 2016 Iran 22/22 37 days 58.59±6.4, 55.21±8.3 3000 mg L-carnitine + other nutrients 
Akbarzadeh et al. 2016 Iran 22/22 23 days 58.72±8.5, 56.90±7.5 3000 mg L-carnitine + other nutrients 
Ghorbani et al. 2017 Iran 10/10 8 weeks 52.7±6.1 500 mg L-carnitine three times a week + exercise 
Ghorbani et al. 2017 Iran 10/10 8 weeks 52.7±6.1 500 mg L-carnitine three times a week + 2000 mg omega 3 + exercise 
Ghorbani et al. 2017 Iran 10/10 8 weeks 52.7±6.1 500 mg L-carnitine three times a week + 2000 mg omega 3 
Parvanova et al. 2018 Italy 110/109 24 weeks >40 2000 mg acetyl L-carnitine + 10 to 20 mg simvastatin 
El-sheikh et al. 2019 Egypt 27/31 24 weeks 59±8.6, 53±8.8 2000 mg L-carnitine + 4 mg glimepiride 
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The effects of L-carnitine supplementation 
on FPG 
Pooling 44 effect sizes from 37 studies, a 
significant reduction was found in FPG fol-
lowing L-carnitine supplementation (WMD): 
-4.57; 95 % CI: -6.88, -2.25) (Table 2 and 
Figure 2A). This finding remained unchanged 
in most subgroup analyses. However, it be-
came non-significant in studies done on par-
ticipants aged <45 years (WMD: -0.55; 95 % 
CI: -1.43, 0.33), studies used L-carnitine in 
dosages of 1,000-2,000 mg/day (WMD: 
 -0.24; 95 % CI: -1.53, 2.00), and those with a 
duration of 3-6 months (WMD: -0.20; 95 % 
CI: -0.76, 0.37), as well as studies done in 
healthy persons (WMD: -0.29; 95 % 
CI: -1.16, 0.59). A significant increase in FPG 
was found in two available studies on patients 
with renal diseases (WMD: 0.63; 95 % CI: 
0.00, 1.27) (Table 3).  
 
 
Table 2: The effects of carnitine supplementation on glycemic control  
VARIABLES NUM-
BER OF 
EFFECT 
SIZES 
WEIGHTED 
MEAN  
DIFFERENCE 
CI 95  % HETEROGENEITY 
I2 (%) P- value  
heterogeneity 
      
FPG 44 -4.57 -6.88, -2.25 95.7 <0.001 
INSULIN 25 -1.21 -1.85, -0.57 89.8 <0.001 
HOMA-IR 21 -0.67 -0.90, -0.44 91.5 <0.001 
HBA1C 26 -0.30 -0.47, -0.13 92.1 <0.001 
FPG: Fasting Plasma Glucose; HOMA-IR: Homeostatic Model Assessment for Insulin Resistance; HbA1c: Hemoglobin A1C 
 
 
 
 
 
 
Figure 2A:        FPG 
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Figure 2B: Insulin 
 
 
 
Figure 2C: HOMA-IR 
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Figure 2D: HbA1c 
 
Figure 2A-D: Meta-analysis of glycemic control weighted mean difference estimates for A) FPG, B) 
insulin, C) HOMA-IR, D) HbA1c in the L-carnitine supplements and placebo groups (CI=95 %). 
Different capital letters indicate various dosage of L-carnitine used and different phases of L-carnitine treatment  
 
 
Table 3: Subgroup analyses for the effects of carnitine supplementation on glycemic control 
VARIABLES SUBGROUPS NUMBER 
OF  
EFFECT 
SIZES 
POOLED 
WMD 
95 % CI I2 (%)
FPG 
 
Participants’ age <45 year 15 -0.55 -1.43, 0.33 80.3 
≥45 year 29 -3.36 -3.81, -2.92 96.9 
Supplement  
dosage 
<1000 mg/day 13 -6.85 -7.59, -6.11 97.5 
1000-2000 mg/day 3 0.24 -1.53, 2.00 00.0 
≥2000 mg/day 28 -1.26 -1.75, -0.77 92.8 
Study duration  <3 month 17 -6.37 -7.07, -5.68 96.7 
3-6 month 16 -0.20 -0.76, 0.37 88.3 
6-12 month 7 -1.79 -2.83, -0.75 95.6 
≥12 month 4 -10.80 -13.01, -8.59 83.6 
Study sample size <50 25 -4.36 -4.96, -3.77 96.2 
50-100 16 -0.95 -1.51, -0.39 94.0 
≥100 3 -8.59 -10.64, -6.54 94.7 
Study location Eastern countries 20 -5.75 -6.42, -5.08 96.4 
Western countries 24 -1.17 -1.67, -0.68 93.7 
Participants’ health 
condition 
 
Healthy 14 -0.29 -1.16, 0.59 77.3 
Renal disease 2 0.63 0.00, 1.27 75.0 
Chronic metabolic  
diseases 
22 -7.97 -8.66, -7.27 96.0 
Cardiovascular disease 3 -4.34 -7.46, -1.22 00.0 
Liver disease 2 -12.74 -15.25, -10.24 71.1 
Other diseases 1 0.90 -1.49, 3.29 - 
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Table 3 (cont.): Subgroup analyses for the effects of carnitine supplementation on glycemic control 
VARIABLES SUBGROUPS NUMBER 
OF  
EFFECT 
SIZES 
POOLED 
WMD 
95 % CI I2 (%)
INSULIN Participants’ age  <45 year 10 -0.23 -0.26, -0.20 84.7 
≥45 year 15 -1.52 -1.90, -1.15 89.2 
Study sample size <50  15 0.01 -0.37, 0.39 83.9 
50-100  7 -0.24 -0.27, -0.21 95.6 
≥100 3 -0.91 -1.39, -0.42 00.0 
Study location Eastern countries 11 -1.68 -2.33, -1.03 76.5 
Western countries 14 -0.24 -0.27, -0.21 92.5 
Supplement  
dosage 
<1000 mg/day 10 -0.23 -0.27, -0.20 79.4 
≥1000 mg/day 15 -0.80 -1.08, -0.51 92.1 
 Study duration <3 month 12 -0.24 -0.27, -0.21 81.7 
  3-6 month 5 -1.53 -2.73, -0.32 59.4 
  6-12 month 6 -0.28 -0.61, 0.04 96.7 
  ≥12 month 2 -1.08 -1.66, -0.50 00.0 
 Participants’ health  Healthy 9 -0.23 -0.26, -0.20 83.7 
 condition Renal disease 1 -7.00 -13.92, -0.08 - 
  Chronic metabolic  
diseases 
10 -1.54 -1.92, -1.15 92.5 
  Cardiovascular disease 3 -0.85 -2.07, 0.37 81.7 
  Liver disease 2 -1.70 -2.79, -0.61 00.0 
HOMA-
IR 
Participants’ age <45 year 8 -0.33 -0.38, -0.28 86.5 
≥45 year 13 -0.81 -0.92, -0.70 90.2 
Study sample size <50  11 -0.63 -0.83, -0.43 67.8 
50-100 7 -0.40 -0.44, -0.35 96.9 
≥100 3 -0.35 -0.61, -0.08 71.4 
Study location Eastern countries 11 -0.35 -0.46, -0.25 74.6 
Western countries 10 -0.42 -0.46, -0.37 95.4 
Participants’ health Healthy 6 -0.35 -0.40, -0.30 89.5 
condition Chronic metabolic  
diseases 
11 -0.35 -0.45, -0.24 92.2 
 Cardiovascular disease 2 -0.65 -0.99, -0.31 00.0 
 Liver disease 2 -0.92 -1.06, -0.78 00.0 
Supplement <2000 mg/day 8 -0.34 -0.39, -0.29 88.6 
dosage ≥2000 mg/day 13 -0.57 -0.65, -0.49 92.1 
Study duration <3 month 10 -0.39 -0.44, -0.34 76.8 
3-6 month 5 -0.42 -0.76, -0.07 25.0 
 6-12 month 4 -0.45 -0.55, -0.36 98.4 
 ≥12 month 2 -0.86 -1.32, -0.39 00.0 
HBA1C 
 
Participants’ age 
 
<45 year 3 -0.12 -0.24, -0.01 94.5 
≥45 year 23 -0.19 -0.24, -0.15 92.1 
Supplement  <2000 mg/day 9 -0.19 -0.28, -0.11 86.4 
dosage ≥2000 mg/day 17 -0.22 -0.28, -0.17 93.7 
Study location Eastern countries 11 -0.10 -0.16, -0.05 65.1 
 Western countries 10 -0.30 -0.37, -0.24 95.4 
Study duration <3 month 9 -0.12 -0.19, -0.06 67.3 
 3-6 month 10 -0.17 -0.23, -0.10 82.2 
 6-12 month 3 -0.23 -0.34, -0.13 98.9 
 ≥12 month 4 -0.78 -0.99, -0.57 81.0 
Study sample size <50  14 -0.13 -0.19, -0.07 63.1 
 50-100 9 -0.22 -0.28, -0.16 96.4 
 ≥100 3 -0.24 -0.36, -0.11 96.4 
FPG: Fasting Plasma Glucose; HOMA-IR: Homeostatic Model Assessment for Insulin Resistance; HbA1c: Hemoglobin A1C 
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The effects of L-carnitine supplementation 
on insulin levels 
Combining 25 effect sizes from 20 stud-
ies, we found a significant reductive effect of 
L-carnitine supplementation on insulin levels 
(WMD: -1.21; 95 % CI: -1.85, -0.57) (Table 
2 and Figure 2B). No significant changes in 
insulin concentrations were found in studies 
which enrolled <50 subjects (WMD: 0.01; 
95 % CI: -0.37, 0.39), studies with a duration 
of 6-12 months (WMD: -0.28; 95 % CI: -0.61, 
0.04), and those done on patients with CVD 
(WMD: -0.85; 95 % CI: -2.07, 0.37) (Table 
3).  
 
The effects of L-carnitine supplementation 
on HOMA-IR 
The pooled analysis of data from 16 studies 
with 21 effect sizes showed a significant re-
duction in HOMA-IR following intake of L-
carnitine supplements (WMD: -0.67; 95 % 
CI: -0.90, -0.44) (Table 2 and Figure 2C). 
This finding remained unchanged in all sub-
group analyses (Table 3). 
 
The effects of L-carnitine supplementation 
on HbA1C 
L-carnitine supplementation resulted in a 
significant reduction in HbA1C concentra-
tions, when we combined data from 22 studies 
with 26 effect sizes (WMD: -0.30; 95 % CI: -
0.47, -0.13) (Table 2 and Figure 2D). This 
finding did not change through subgroup 
analyses (Table 3). 
 
DISCUSSION 
This is the first meta-analysis of RCTs an-
alyzing the effect of carnitine supplementa-
tion on glucose homeostasis parameters. In 
the present study, we showed that carnitine 
supplementation can significantly reduce 
FPG, insulin, HOMA-IR, and HbA1c levels. 
Previous evidence suggested that car-
nitine might have a positive impact on glyce-
mic control. A meta-analysis by Xu et al. (Xu 
et al., 2017) indicated that carnitine supple-
mentation had beneficial effects on HOMA-
IR score. Supplementation with carnitine at a 
dosage of 2 g/day for 4 weeks in patients with 
impaired glucose metabolism was associated 
with a significant reduction of insulin levels 
and HOMA-IR score. In a trial by Bae et al. 
(2015), carnitine supplementation resulted 
with a significant decrease in fasting glucose, 
HbA1c, and HOMA-IR score. Opposite find-
ings were also reported. For example, Liang 
et al. (1998) were unable to find any signifi-
cant effects of carnitine on FPG, HbA1c, or 
insulin levels.  
Different dosages of carnitine, different 
types of carnitine as well as the use of only 
carnitine or carnitine combined with other 
supplements, heterogeneity in design of stud-
ies, and differences in populations involved in 
studies are some of the possible reasons that 
may explain different results. When patients 
with T2DM have other risk factors, particu-
larly components of MetS, they are at espe-
cially high risk for CVD (Grundy et al., 
2004). In order to prevent CVD, control of 
blood glucose and other CVD risk factors in 
these patients is very important (Gæde et al., 
2003). Due to changed insulin secretion and 
pancreatic beta cell function normal glucose 
equilibrium is in this condition impaired (Xia 
et al., 2012). Several mechanisms have been 
suggested as possible explanations for benefi-
cial effects of carnitine on fasting glucose and 
insulin resistance. Increasing mitochondrial 
oxidation of long-chain acyl-CoAs is one of 
important mechanisms by which carnitine 
could improve glycemic control (Kerner and 
Hoppel, 2000; McGarry and Brown, 1997). It 
has been shown that carnitine supplementa-
tion reduces oxidative stress in diabetic pa-
tients (Malaguarnera et al., 2009a). Carnitine 
supplementation may have beneficial effects 
on glucose homeostasis also by modulating 
the expression of genes involved in insulin 
signaling pathway, changing the expression 
of gluconeogenic and glycolytic enzymes, 
regulating the intra-mitochondrial acyl-
CoA/CoA ratio, and modulating the activity 
of pyruvate dehydrogenase complex (Steiber 
et al., 2004).  
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CONCLUSIONS 
This meta-analysis has shown that L-car-
nitine supplementation significantly reduces 
FPG, insulin, HOMA-IR, and HbA1c levels. 
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